Log in
NASDAQ:UTHR

United Therapeutics Stock Forecast, Price & News

$132.64
-2.90 (-2.14 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$131.96
Now: $132.64
$136.98
50-Day Range
$104.01
MA: $129.86
$142.93
52-Week Range
$75.58
Now: $132.64
$144.26
Volume521,850 shs
Average Volume509,832 shs
Market Capitalization$5.89 billion
P/E Ratio13.62
Dividend YieldN/A
Beta0.71
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292
Employees920

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.45 billion
Book Value$63.36 per share

Profitability

Net Income$-104,500,000.00

Miscellaneous

Market Cap$5.89 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$132.64
-2.90 (-2.14 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

How has United Therapeutics' stock been impacted by COVID-19?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UTHR shares have increased by 41.1% and is now trading at $132.64.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of United Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for United Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than United Therapeutics?

Wall Street analysts have given United Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but United Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for United Therapeutics
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) issued its earnings results on Wednesday, October, 28th. The biotechnology company reported $3.84 EPS for the quarter, beating analysts' consensus estimates of $2.41 by $1.43. The biotechnology company had revenue of $380.10 million for the quarter, compared to analyst estimates of $357.95 million. United Therapeutics had a net margin of 30.04% and a return on equity of 14.90%. The business's revenue was down 5.3% on a year-over-year basis. During the same period last year, the company earned $3.83 earnings per share.
View United Therapeutics' earnings history
.

What price target have analysts set for UTHR?

8 Wall Street analysts have issued 1-year price targets for United Therapeutics' shares. Their forecasts range from $80.00 to $255.00. On average, they expect United Therapeutics' share price to reach $146.00 in the next twelve months. This suggests a possible upside of 10.1% from the stock's current price.
View analysts' price targets for United Therapeutics
.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 65, Pay $2.98M)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 48, Pay $1.8M)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 52, Pay $1.3M)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $1.53M)
  • Mr. Dewey Steadman C.F.A., CFA, Head of Investor Relations
  • Ms. Holly Hobson, Associate VP of HR
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics
  • Mr. Patrick Poisson, Exec. VP of Technical Operations (Age 52)
  • Leigh Peterson, VP of Product Devel.
  • Mr. Shola Oyewole, VP of Digital Innovation

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.69%), State Street Corp (3.40%), Acadian Asset Management LLC (2.85%), AQR Capital Management LLC (2.12%), First Trust Advisors LP (1.91%) and Great Point Partners LLC (1.44%). Company insiders that own United Therapeutics stock include Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics
.

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, BlackRock Inc., Wells Fargo & Company MN, Greylin Investment Mangement Inc., BNP Paribas Arbitrage SA, Tang Capital Management LLC, Wedge Capital Management L L P NC, and Mackay Shields LLC. Company insiders that have sold United Therapeutics company stock in the last year include Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner, and Tommy G Thompson.
View insider buying and selling activity for United Therapeutics
.

Which major investors are buying United Therapeutics stock?

UTHR stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Point72 Asset Management L.P., AJO LP, Royce & Associates LP, Acadian Asset Management LLC, LSV Asset Management, JPMorgan Chase & Co., and Cubist Systematic Strategies LLC.
View insider buying and selling activity for United Therapeutics
.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $132.64.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $5.89 billion and generates $1.45 billion in revenue each year. The biotechnology company earns $-104,500,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. United Therapeutics employs 920 workers across the globe.

What is United Therapeutics' official website?

The official website for United Therapeutics is www.unither.com.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.